Short answer
Kura Oncology, Inc. (KURA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $23M (up 10.1% year over year) with net income of −$70M.
Q3 2026 key financials · XBRL
- Revenue
- $23M
- +10.1% YoY · +9.4% QoQ
- Net income
- −$70M
- +5.3% YoY · −2.8% QoQ
- Operating margin
- -326.9%
- EPS (diluted)
- −$0.78
- +8.2% YoY · −1.3% QoQ
Source: XBRL data from the Kura Oncology, Inc. (KURA) Q3 2026 10-Q on SEC EDGAR. USD.
Kura Oncology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $22.8M, versus $20.8M collaboration revenue last year, with $13.9M KOMZIFTI product revenue
- Collaboration revenue $8.9M, down $11.8M year over year from $20.8M
- R&D expenses $66.9M, down from $67.9M, while SG&A declined to $30.2M from $32.8M
- Cash, cash equivalents and short-term investments $492.1M at September 30, 2026, sufficient to fund operations into 2028
- Net cash used in operating activities $202.8M, up from $181.3M, while ATM proceeds totaled $31.5M
- Outlook: R&D and SG&A expected to increase, with additional financing required and Phase 3 topline results anticipated in 2028
Risk Factors
- Newly added commercialization risk: limited experience marketing KOMZIFTI, triggered by its first commercial launch as the company’s first approved product
- Most materially updated regulatory risk: FDA post-approval commitments include pediatric, long-term safety, renal/hepatic impairment, drug-interaction and companion-diagnostic studies
- New compliance exposure: healthcare fraud and abuse laws, including Anti-Kickback Statute, False Claims Act and Sunshine Act requirements
- Near-term market risk: KOMZIFTI competes with FDA-approved REVUFORJ and established AML therapies
- Financial risk: continued losses and potential need for substantial additional capital, creating dilution or operating restrictions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kura Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.